



DVS

Thermo coagulation as a treatment of the great saphenous vein insufficiency and his tributaries: preliminary analysis

(Sarah Thomis)

October 31, 2012

Contents

1. Descriptive statistics	1
1.1. Patient characteristics	1
1.2. Side effects	2
1.3. Outcome measurements	5
2. Main analysis: occlusion overall	7
3. Secondary analysis: occlusion at specific locations	8
4. Secondary analysis: quality of life, pain, patient satisfaction, duplex control	9
4.1. Quality of life	9
4.2. Pain	10
4.3. Patient satisfaction	11
4.4. Duplex control	12

1. Descriptive statistics

1.1. Patient characteristics

Continuous variables

variable	Statistics							
	N	mean	std	median	min	max	Q1	Q3
age	40	50.1	14.9	50.5	19.0	84.0	42.0	62.5
CEAP (1-6)	40	2.3	0.9	2.0	1.0	6.0	2.0	2.0
BMI	40	25.2	4.5	24.9	17.6	38.2	22.3	27.5
Total Joules	40	7365.8	2258.6	7607.5	3025.0	12350.0	6100.0	8637.5

Discrete variables

gender		
gender	Frequency	Percent
M	12	30.00
V	28	70.00

profession: S/E			
profession	S	E	Percent
afwisselend		1	2.50
staand		22	55.00
zittend		17	42.50

CEAP (1-6)			
CEAP_1_6_	Frequency	Percent	
1	1	2.50	
2	34	85.00	
4	3	7.50	
5	1	2.50	
6	1	2.50	

1.2. Side effects

Incapacity to work

variable	Statistics							
	N	mean	std	median	min	max	Q1	Q3
Incapacity to work (days)	40	10.2	9.0	10.0	0.0	30.0	2.0	14.0

Pain killers

variable	Statistics							
	N	mean	std	median	min	max	Q1	Q3
total numbers of analgetcs	40	0.7	1.1	0.0	0.0	3.0	0.0	1.0
days of analgetics intake	40	0.9	1.8	0.0	0.0	7.0	0.0	1.0

total numbers of analgetcs

total_numbers_of_analgetcs	Frequency	Percent
0	25	62.50
1	7	17.50
2	3	7.50
3	5	12.50

days of analgetics intake

days_of_analgetics_intake	Frequency	Percent
0	25	62.50
1	10	25.00
2	1	2.50
4	1	2.50
5	1	2.50
7	2	5.00

Ecchymosis

variable	Statistics							
	N	mean	std	median	min	max	Q1	Q3
ecchymosis score d7)	40	0.02	0.04	0.00	0.00	0.13	0.00	0.03

ecchymosis score d7)		
ecchymosis_score_d7_	Frequency	Percent
0	28	70.00
0.022	1	2.50
0.023	1	2.50
0.027	1	2.50
0.031	1	2.50
0.047	1	2.50
0.058	1	2.50
0.07	1	2.50
0.072	1	2.50
0.08	1	2.50
0.1	1	2.50
0.12	1	2.50
0.13	1	2.50

Periphlebitis

variable	Statistics							
	N	mean	std	median	min	max	Q1	Q3
periphlebitis (days)	40	1.1	2.8	0.0	0.0	14.0	0.0	0.0

periphlebitis (days)		
periphlebitis__days_	Frequency	Percent
0	33	82.50
2	1	2.50
3	1	2.50
5	2	5.00
7	2	5.00
14	1	2.50

Paresthesia

paresthesia: 0-1		
paresthesia_____0_1	Frequency	Percent
0	40	100.00

1.3. Outcome measurements

Vein diameter Preop

variable	Statistics							
	N	mean	std	median	min	max	Q1	Q3
mean diameter vein (mm)	40	6.5	1.6	6.3	4.2	11.5	5.6	7.6
diameter cross (mm)	40	7.9	2.0	7.8	4.3	12.6	6.3	9.4
diameter knie (mm)	38	5.8	2.0	5.7	2.8	13.7	4.2	6.6
diameter middij (mm)	40	5.9	1.4	5.8	3.3	8.7	4.8	7.1

Vein diameter 1 month postop

variable	Statistics							
	N	mean	std	median	min	max	Q1	Q3
mean diameter vein (mm)1	40	6.3	1.5	6.0	3.6	9.6	5.3	7.4
diameter cross (mm)1	40	7.7	2.3	7.9	3.4	14.8	6.2	8.8
diameter knie (mm)1	37	5.2	1.5	4.9	1.9	7.6	4.3	6.4
diameter middij (mm)1	40	5.8	1.3	5.8	3.0	8.6	4.8	6.5

Quality of life

variable	Statistics							
	N	mean	std	median	min	max	Q1	Q3
QOL	40	35.1	10.7	32.5	20.0	65.0	27.5	39.0
QOL d7	40	38.5	14.6	33.5	20.0	74.0	28.0	47.0
QOL 1M	40	27.0	6.9	24.5	20.0	45.0	22.0	29.5

Pain

variable	Statistics							
	N	mean	std	median	min	max	Q1	Q3
painscore d2: 0-10	40	2.5	2.2	2.0	0.0	7.0	1.0	4.0
painscore d5: 0-10	40	2.0	1.7	2.0	0.0	7.0	0.5	3.0
painscore d7: 0-10	40	1.6	1.8	1.0	0.0	8.0	0.0	3.0
painscore d10 (0-10)	40	0.6	0.9	0.0	0.0	3.0	0.0	1.0

Patient satisfaction

variable	Statistics							
	N	mean	std	median	min	max	Q1	Q3
patient_satisfaction	40	8.9	1.0	9.0	6.0	10.0	9.0	10.0

2. Main analysis: occlusion overall

		95% confidence interval		
	Difference estimate	Lower Limit	Upper Limit	P-value
Improvement at 1 month compared to preop?	-0.22	-0.56	0.13	0.2075

A positive (negative) difference estimate indicates increase (decrease) over time

3. Secondary analysis: occlusion at specific locations

	Difference estimate	95% confidence interval		P-values	
		Lower Limit	Upper Limit	Raw	Corrected (Holm)
Cross: Improvement at 1 month compared to preop?	-0.17	-0.79	0.46	0.5948	0.6019
Knee: Improvement at 1 month compared to preop?	-0.63	-1.16	-0.10	0.0214	0.0643
Mid Thigh: Improvement at 1 month compared to preop?	-0.17	-0.49	0.16	0.3010	0.6019

A positive (negative) difference estimate indicates increase (decrease) over time


4. Secondary analysis: quality of life, pain, patient satisfaction, duplex control

4.1. Quality of life


	Difference estimate	95% confidence interval		P - values	
		Lower Limit	Upper Limit	Raw	Bonferroni
QOL: change over time	.	.	.	0.0000	.
Improvement at 1 week compared to preop?	3.40	-0.54	7.34	0.0900	0.2700
Improvement at 1 month compared to preop?	-8.12	-11.78	-4.47	0.0000	0.0001
Change between 1 week and 1 month?	-11.52	-15.35	-7.70	0.0000	0.0000

A positive (negative) difference estimate indicates increase (decrease) over time

4.2. Pain



4.3. Patient satisfaction




4.4. Duplex control

Frequencies and percentages of duplex-scores at 1 and 6 months

Lev score (duplex)	1 Month		6 Month	
	N	Percentage	N	Percentage
0	0	0.0	1	2.5
1b	0	0.0	2	5.0
2a	34	85.0	0	0.0
2b	6	15.0	4	10.0
3	0	0.0	23	57.5
4	0	0.0	10	25.0

Graphical presentation



Frequencies and percentages of patients with improvement, stability, worsening

change	Frequency	Percent
Worsening	3	7.50
Improvement	37	92.50

Signed rank test for difference in level between 1 and 6 months

Test	Statistic	P-value
Signed Rank	348.50	<.0001